SS-31 Protects Mitochondrial Function and Improves Exercise Capacity in Heart Failure

SS-31 is one of the few compounds with human clinical data showing it can protect mitochondria when they're under metabolic stress. What makes this compelling isn't just the heart failure application—it's proof of concept that mitochondrial-targeted peptides can restore cellular energy production in real human tissue. Your mitochondria are the rate-limiting step in almost everything: energy, recovery, cognition, longevity. SS-31 appears to protect the inner mitochondrial membrane where ATP gets made, preventing the oxidative damage that accumulates with age and stress. While this study focused on cardiac patients, the mitochondrial dysfunction it addresses—impaired respiration, oxidative stress, energy deficit—is universal to aging and metabolic decline.

SS-31 (also known as Elamipretide or Bendavia) was developed specifically to target mitochondria through a unique mechanism: it concentrates in the inner mitochondrial membrane and stabilizes cardiolipin, a phospholipid critical for optimal mitochondrial function. This 2016 study was part of clinical trials that advanced SS-31 to Phase III development for heart failure and other mitochondrial diseases. While the drug's commercial path has been complex, the human data established clear proof that targeting mitochondrial membrane function can translate to measurable clinical benefits. The peptide's ability to improve cardiac energetics (measured via phosphocreatine/ATP ratios) demonstrated that it wasn't just reducing symptoms—it was addressing fundamental energy metabolism at the cellular level.

Elamipretide Improves Mitochondrial Function in the Failing Human Heart